This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Ibrutinib
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <StructureSection load='' size='340' side='right' caption=' | + | <StructureSection load='' size='340' side='right' caption='Ibrutinib' scene='99/997914/Cv/1'> |
Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's [[tyrosine kinase]] (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia.<ref name="a5">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44 "Imbruvica- ibrutinib capsule Imbruvica- ibrutinib tablet, film coated".] DailyMed. 8 April 2020. Retrieved 21 April 2020.</ref><ref name="a6">[https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica "Imbruvica EPAR".] European Medicines Agency (EMA). 8 July 2021. Retrieved 14 July 2021.</ref> See also [https://en.wikipedia.org/wiki/Ibrutinib Ibrutinib]. | Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's [[tyrosine kinase]] (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia.<ref name="a5">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44 "Imbruvica- ibrutinib capsule Imbruvica- ibrutinib tablet, film coated".] DailyMed. 8 April 2020. Retrieved 21 April 2020.</ref><ref name="a6">[https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica "Imbruvica EPAR".] European Medicines Agency (EMA). 8 July 2021. Retrieved 14 July 2021.</ref> See also [https://en.wikipedia.org/wiki/Ibrutinib Ibrutinib]. | ||
Current revision
| |||||||||||
References
- ↑ "Imbruvica- ibrutinib capsule Imbruvica- ibrutinib tablet, film coated". DailyMed. 8 April 2020. Retrieved 21 April 2020.
- ↑ 2.0 2.1 "Imbruvica EPAR". European Medicines Agency (EMA). 8 July 2021. Retrieved 14 July 2021.
